Elizabeth Holmes doc 'You Can See Everything' posts second-biggest doc debut ever

The Elizabeth Holmes documentary 'You Can See Everything' just scored the second-biggest opening weekend ever for a documentary film, according to TechCrunch. That puts the film behind only one other documentary in the genre's history, a remarkable feat for a story that has already been told in podcasts, books, and a scripted series. The debut is a clear signal that audiences are still hungry for the Theranos saga, and it has immediate implications for media executives, founders, and investors.

The film, which chronicles Holmes's rise as a Silicon Valley phenom and her fall as a convicted fraudster, is drawing viewers who remember the breathless coverage of her black turtlenecks and the $9 billion valuation that evaporated. For anyone who has followed the story, the documentary's performance is a reminder that the public's appetite for accountability narratives hasn't faded. It also raises the bar for documentary marketing and distribution, proving that a well-told true-crime story can compete with big-budget theatrical releases.

For context, Theranos was a blood-testing startup that promised to run dozens of diagnostic tests on a single drop of blood. Holmes raised hundreds of millions from blue-chip investors, including Walgreens and Rupert Murdoch, before investigative reporting revealed the technology was largely a sham. She was convicted on multiple counts of fraud and is currently serving a prison sentence. The documentary adds a new layer to that story, offering a fresh perspective on how a young founder fooled so many sophisticated people.

The documentary's strong opening is not an isolated event. It follows a wave of true-crime and fraud documentaries that have become cultural touchstones, from 'The Tinder Swindler' to 'Fyre' to 'Inventing Anna.' For media executives, the numbers are a green light: audiences will pay attention to stories about deception, especially when they involve real money and real consequences. Streaming platforms have already poured billions into documentary slates, and this performance will likely accelerate those investments. The second-biggest opening weekend ever is a benchmark that will be cited in pitch meetings for years.

For founders and operators, the film's popularity is a cautionary tale with a commercial twist. The Theranos story is now a permanent part of startup lore, a case study in how charisma and fake-it-till-you-make-it can go catastrophically wrong. Investors who backed Holmes, and the board members who enabled her, are now part of the narrative. The film's success means that scrutiny of founder behavior isn't going away; if anything, it's becoming entertainment. That's a sobering thought for anyone building a company today, because the line between visionary and fraudster can look thin in hindsight.

The strategic stakes extend beyond media. For venture capitalists and board members, the enduring interest in Theranos is a reminder that governance failures have long tails. Every new documentary, podcast, or book about the company keeps the lessons fresh in the minds of limited partners, regulators, and the public. That's why some firms have tightened due diligence and added founder-integrity checks. The documentary's box-office performance is a proxy for how much attention these issues still command, and it suggests that the reputational damage from a Theranos-style collapse can persist for decades.

There's also a lesson in the film's title itself. 'You Can See Everything' hints at the idea that the warning signs were visible all along, if only investors and board members had looked closely enough. That framing resonates in a post-Theranos world where every startup pitch is now met with a little more skepticism. For executives, the documentary is a reminder that transparency isn't just a virtue; it's a risk-management tool. The more you hide, the more interesting you become to documentarians.

In the end, 'You Can See Everything' is more than a documentary; it's a cultural event that quantifies our collective fascination with fraud. For decision-makers, the takeaway is twofold: there's money to be made in telling these stories well, and there's reputational risk in becoming the subject of one. The second-biggest opening weekend ever is a reminder that the audience is watching, and they're not going to look away. Whether you're a media executive greenlighting the next true-crime project or a founder trying to build trust, the message is the same: the story matters, and so does the way you tell it.